News | News By Subject | News by Disease News By Date | Search News

ALS (Lou Gehrig's disease) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Mitsubishi Tanabe Wins FDA Approval for Radicava, the First New ALS Drug in 22 Years     5/8/2017
Comeback Kid Cytokinetics (CYTK) Pockets $95 Million Upfront in R&D Deal With Astellas (ALPMY), Needs Results for More     7/27/2016
Iron Horse Therapeutics Launched By Avalon Ventures and GlaxoSmithKline (GSK)     11/10/2015
Biogen (BIIB), the ALS Association and Columbia University Medical Center to Map ALS With Ice Bucket Cash     8/18/2015
How Cytokinetics (CYTK) Will Be Getting Some of That Ice Bucket Challenge Cash     7/15/2015
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation     4/22/2015
Biogen (BIIB) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS     3/24/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Despite Conflicting Data, Cytokinetics, Inc. (CYTK) Plans To Take ALS Drug Into Late Stage Study     10/21/2014
BrainStorm Cell Therapeutics Inc. Nabs FDA Fast-Track Status For ALS Stem Cell Therapy     10/8/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Poaches Renowned Neurologist From Novartis AG (NVS) To Lead ALS Innovation Hub     8/27/2014
Bay Area's Cytokinetics, Inc. (CYTK) Plummets As ALS Drug Fails Phase 2B Study; Stock Down -64.67% At Market Close (April 25, 2014)     4/28/2014
BrainStorm Cell Therapeutics Inc. Says Stem Cells Helped 75-Year Old Patient With ALS And MG     1/7/2014

News from Around the Web
How AI Robots Hunt New Drugs For Crippling Nerve Disease     8/10/2017
ALS Patients Communicate for First Time in Years With New Device, PLoS Biology Reveals     2/1/2017
One Gene Predicts Rapid ALS Progression 80 Percent of the Time, Methodist Neurological Institute Study     12/10/2012
Stem Cell Model Offers Clues to Cause of Inherited ALS, University of California, San Diego (UCSD) Study     6/22/2011
Ring Finger Length Linked to ALS, King's College London Study Suggests     5/10/2011
Vitamin E Users Show Lower ALS Risk, Harvard University Study     3/17/2011
Cigarette Smoking May Increase Risk of Muscle-Wasting Disease, Harvard School of Public Health Study     2/15/2011
Blue-green Algae Tested for Treating ALS, University of South Florida Study     12/22/2010
Genetic Variations Linked to ALS Risk, University Of Montreal Study     8/31/2010
Brain Trauma Can Mimic Lou Gehrig's Disease, Veterans Affairs Medical Center and Boston University School of Medicine Study     8/18/2010
Cleveland Clinic Researcher Finds Treatment Eases Involuntary Laughing, Crying Tied to Alzheimer's, MS     4/16/2010
Lithium Shows No Benefit in ALS, Massachusetts General Hospital Study     4/6/2010
Compound Shows Potential For Slowing Progression Of Lou Gehrig's Disease, University of Rochester Medical Center Study     10/20/2009
Novel Human Stem Cell-based Model Of Amyotrophic Lateral Sclerosis Opens Doors For Rapid Drug Screening, Salk Institute for Biological Studies Study     12/5/2008
Neurons Derived From Embryonic Stem Cells Restore Muscle Function After Injury, Dalhousie University Study     11/21/2008

Press Releases
Cytokinetics (CYTK) Announces Start Of FORTITUDE-ALS, A Phase II Clinical Trial Of CK-2127107 In Patients With Amyotrophic Lateral Sclerosis     7/27/2017
FDA Grants Fast Track Designation To Flex Pharma (FLKS)’s FLX-787 For The Treatment Of Severe Muscle Cramps Associated With ALS     7/25/2017
BrainStorm Cell Announces Agreement With University of California, Irvine Medical Center To Participate In Phase III Trial Of NurOwn In ALS     7/25/2017
BrainStorm Cell Awarded $16 Million Non-Dilutive Grant From CIRM In Support Of Phase III Clinical Trial Of NurOwn In ALS     7/21/2017
BrainStorm Cell Announces Agreements With Massachusetts General Hospital And California Pacific Medical Center To Participate In Phase III Trial Of NurOwn In ALS     7/18/2017
Neuraltus Pharmaceuticals, Inc. Announces Completion Of Enrollment In Confirmatory Phase II Study Of NP001 In ALS Patients With Systemic Inflammation     7/12/2017
Worldwide Clinical Trials Selected By BrainStorm Cell As CRO For Phase III NurOwn Trial In ALS     7/5/2017
MT Pharma America Enrolls More Than 700 Sites Of Care In Newly Created National Infusion Center Directory For ALS Patients     7/5/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients     6/21/2017
ProMis Neurosciences Identifies Novel Therapeutic Epitope Target For ALS And Dementia     5/31/2017
CRISPR (CRSP) And Collaborators At The University of Florida Awarded Target ALS Grant To Develop CRISPR/Cas9-Based Approaches For ALS     5/16/2017
French Regulators Order AB Science (AB.PA) To Temporarily Suspend Work On Phase III ALS Trial     5/12/2017
MediciNova, Inc. Announces Exploratory Interim Clinical Outcomes Data From Clinical Trial Of MN-166 (Ibudilast) In ALS Presented At The American Academy of Neurology 69th Annual Meeting In Boston     4/26/2017
Neuraltus Pharmaceuticals, Inc. Release: Retrospective Analysis Finds Amyotrophic Lateral Sclerosis Patients With High Serum C-Reactive Protein (CRP) Levels May Respond To Immune Regulators Like NP001     4/4/2017
Neuraltus Pharmaceuticals, Inc. Provides Enrollment Update On Confirmatory Phase II Study Of NP001 In ALS     2/9/2017